<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04965870</url>
  </required_header>
  <id_info>
    <org_study_id>2021-01</org_study_id>
    <nct_id>NCT04965870</nct_id>
  </id_info>
  <brief_title>A Study of Trifluridine/ Tipiracil in Chemorefractory mCRC in Greece</brief_title>
  <acronym>RETRO-TAS</acronym>
  <official_title>A Retrospective Observational Study of Trifluridine/ Tipiracil (TAS-102) in Chemorefractory Metastatic Colorectal Cancer (mCRC) in Greece. Real World Data on Clinical Benefit.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hellenic Study Group of Psychoneuroimmunology in Cancer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Servier</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hellenic Study Group of Psychoneuroimmunology in Cancer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Collection of real world data on the clinical efficacy of trifluridine/ tipiracil (FTD/TPI)&#xD;
      in the Greek population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this analysis is to record clinical practice and to collect real world data on the&#xD;
      clinical efficacy of trifluridine/ tipiracil (FTD/TPI) in the Greek population. Main&#xD;
      objectives include to assess physician's choice of treatment in chemoresistant metastatic&#xD;
      colorectal cancer with FTD/TPI in third line and beyond In addition, the clinicopathologic&#xD;
      features related to metastatic colorectal cancer (focus on molecular profile), duration of&#xD;
      treatment, dose modification and toxicity will be analyzed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2021</start_date>
  <completion_date type="Anticipated">December 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Retrospective data analysis from January 2018 to at least 3 months prior to being included in the study.</time_frame>
    <description>PFS is defined as the time interval from initiation of treatment to the first date of documented tumor progression or death from any cause, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Retrospective data analysis from January 2018 to at least 3 months prior to being included in the study.</time_frame>
    <description>Overall survival is defined as the time interval from initiation of treatment to the date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival rate at 6 and 8 months</measure>
    <time_frame>Retrospective data analysis from January 2018 to at least 3 months prior to being included in the study.</time_frame>
    <description>PFS rate at 6 and 8 months corresponding to the percentage of patients surviving without any documented progression of the disease at 6 and 8 months after treatment initiation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>Retrospective data analysis from January 2018 to at least 3 months prior to being included in the study.</time_frame>
    <description>The DCR is defined as the proportion of patients with objective evidence of complete response (CR), the proportion of patients with objective evidence of partial response (PR), and the proportion of patients with objective evidence of stable disease (SD).</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trifluridine/Tipiracil</intervention_name>
    <description>Trifluridine/ Tipiracil is an oral combination of an antineoplastic thymidine-based nucleoside analogue, trifluridine, and the thymidine phosphorylase (TPase) inhibitor, tipiracil hydrochloride.</description>
    <other_name>FTD/TPI</other_name>
    <other_name>TAS 102</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Greek patients with mCRC&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Histologically confirmed metastatic colorectal cancer&#xD;
&#xD;
          -  Available data on previous chemotherapy lines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        No exclusion criteria have been established for this observational and retrospective study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ANNA KOUMARIANOU, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>4th Department of Internal Medicine, Attikon University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Koumarianou MD, Consultant in Medical Oncology</last_name>
    <phone>30210 5831687</phone>
    <email>akoumari@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anastasios Ntavatzikos, MD</last_name>
    <email>dmaal2@yahoo.gr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University General Hospital of Heraklion (PAGNI)</name>
      <address>
        <city>Heraklion</city>
        <state>Crete</state>
        <zip>70013</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ioannis Souglakos, As. Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital &quot;Venizeleio - Pananio&quot;</name>
      <address>
        <city>Heraklion</city>
        <state>Crete</state>
        <zip>71409</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikolaos Androulakis, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Athens Medical Group</name>
      <address>
        <city>Athens</city>
        <zip>11525</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michalis Karamouzis, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Oncological Hospital &quot;Agioi Anargyroi&quot;</name>
      <address>
        <city>Athens</city>
        <zip>14564</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iosif Sgouros, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Eleni Res, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Attikon University Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Koumarianou, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Anticancer Hospital &quot;METAXA&quot;</name>
      <address>
        <city>Piraeus</city>
        <zip>18537</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Spyridon Xynogalos, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Xristos Kosmas, MD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 28, 2021</study_first_submitted>
  <study_first_submitted_qc>July 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2021</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trifluridine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

